Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males

NCT00522431 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT00522431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
March 31, 2008
Enrollment
149 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism